VICTOR A. LEVIN, M.D.
Neurology at Holcombe Blvd, Houston, TX

6653351, Nov 25, 2003

Aug 13, 2002

10/218097

Victor A. Levin - Houston TX

Board of Regents, The University of Texas System - Austin TX

A61K 31195

514564, 514283

The present invention provides a combination therapy using eflomithine (DFMO) and PCV (matulane, lomustine and vincristine) in the treatment of anaplastic gliomas. In contrast to the results seen with glioblastoma multiforme, anaplastic gliomas responded better to the combination of DFMO and PCV than to either the PCV combination or DFMO alone, extending patient survival by approximately two years.

2007019, Aug 23, 2007

Jan 22, 2007

11/625520

Victor Levin - Houston TX, US
Ehud Mendel - Columbus OH, US

A61K 51/04

424001650

The present invention provides methods for the treatment of tumors, such as spinal metastases, using compositions that permit the introduction of chemotherapeutics intratumorally while concurrently visualizing the procedure. Thus, in certain embodiments, the invention concerns a composition comprising a chemotherapeutic, an alcohol and an iodinated contrast agent (e.g., iodouracil) that may be introduced into the tumor by direct injection through the aid of an imaging device, such as a CT scanner, x-ray machine, fluoroscope or the like. The ability to visualize drug solution permits the faithful introduction of the drug directly into the tumor, as opposed to surrounding tissues, which is enabled through the use of the contrast medium.

2005026, Nov 24, 2005

Mar 15, 2005

11/080248

Juan Fueyo - Houston TX, US
Athanassios Kyritsis - Stavraki, GR
W. K. Yung - Houston TX, US
Polly Lee - Houston TX, US
Victor Levin - Houston TX, US
Charles Conrad - Spring TX, US
Frederick Lang - Houstoon TX, US

C12Q001/68, A61K048/00, C12N015/861

424093200, 435456000

The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.

2003013, Jul 24, 2003

Apr 17, 2002

10/124608

Juan Fueyo - Houston TX, US
Athanassios Kyritsis - Stavraki, GR
Polly Lee - Houston TX, US
Victor Levin - Houston TX, US
Charles Conrad - Spring TX, US
Frederick Lang - Houston TX, US

A61K048/00, C12N007/00, C12N015/861

424/093200, 435/235100, 435/456000

The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.

6100254, Aug 8, 2000

Oct 10, 1997

8/948839

Raymond J. A. Budde - Bellaire TX
Jonathan A. Ellman - Oakland CA
Victor A. Levin - Houston TX
Gary E. Gallick - Kingwood TX
Robert A. Newman - Sugar Land TX

Board of Regents, The University of Texas System - Austin TX
The Regents of the University of California - Oakland CA

A61K 315513, A61P 2500, C07D24316

514221

Disclosed herein are small molecule, non-peptidyl inhibitors of protein tyrosine kinases, and methods for their use. The instant inhibitors are based on a 1,4-benzodiazepin-2-one nucleus. Methods are provided for inhibition of specific protein tyrosine kinases, for example pp60. sup. c-src. Methods are further provided for the use of these inhibitors in situations where the inhibition of a protein tyrosine kinase is indicated, for example, in the treatment of certain diseases in mammals, including humans.